Literature DB >> 23169451

A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse.

Angèle Nalbandian1, Katrina J Llewellyn, Mallikarjun Badadani, Hong Z Yin, Christopher Nguyen, Veeral Katheria, Giles Watts, Jogeshwar Mukherjee, Jouni Vesa, Vincent Caiozzo, Tahseen Mozaffar, John H Weiss, Virginia E Kimonis.   

Abstract

INTRODUCTION: Mutations in the valosin-containing protein (VCP) gene cause hereditary inclusion body myopathy (IBM) associated with Paget disease of bone (PDB), and frontotemporal dementia (FTD). More recently, these mutations have been linked to 2% of familial amyotrophic lateral sclerosis (ALS) cases. A knock-in mouse model offers the opportunity to study VCP-associated pathogenesis.
METHODS: The VCP(R155H/+) knock-in mouse model was assessed for muscle strength and immunohistochemical, Western blot, apoptosis, autophagy, and microPET/CT imaging analyses.
RESULTS: VCP(R155H/+) mice developed significant progressive muscle weakness, and the quadriceps and brain developed progressive cytoplasmic accumulation of TDP-43, ubiquitin-positive inclusion bodies, and increased LC3-II staining. MicroCT analyses revealed Paget-like lesions at the ends of long bones. Spinal cord demonstrated neurodegenerative changes, ubiquitin, and TDP-43 pathology of motor neurons.
CONCLUSIONS: VCP(R155H/+) knock-in mice represent an excellent preclinical model for understanding VCP-associated disease mechanisms and future treatments.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23169451      PMCID: PMC3556223          DOI: 10.1002/mus.23522

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  67 in total

1.  Functional analysis of the trypanosomal AAA protein TbVCP with trans-dominant ATP hydrolysis mutants.

Authors:  J R Lamb; V Fu; E Wirtz; J D Bangs
Journal:  J Biol Chem       Date:  2001-03-09       Impact factor: 5.157

Review 2.  Cdc48-Ufd1-Npl4: stuck in the middle with Ub.

Authors:  Nathan W Bays; Randolph Y Hampton
Journal:  Curr Biol       Date:  2002-05-14       Impact factor: 10.834

Review 3.  Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia.

Authors:  R S Turner; L C Kenyon; J Q Trojanowski; N Gonatas; M Grossman
Journal:  Ann Neurol       Date:  1996-02       Impact factor: 10.422

4.  Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia.

Authors:  M J Kovach; B Waggoner; S M Leal; D Gelber; R Khardori; M A Levenstien; C A Shanks; G Gregg; M T Al-Lozi; T Miller; W Rakowicz; G Lopate; J Florence; G Glosser; Z Simmons; J C Morris; M P Whyte; A Pestronk; V E Kimonis
Journal:  Mol Genet Metab       Date:  2001-12       Impact factor: 4.797

5.  VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration.

Authors:  M Hirabayashi; K Inoue; K Tanaka; K Nakadate; Y Ohsawa; Y Kamei; A H Popiel; A Sinohara; A Iwamatsu; Y Kimura; Y Uchiyama; S Hori; A Kakizuka
Journal:  Cell Death Differ       Date:  2001-10       Impact factor: 15.828

6.  Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone.

Authors:  Sara K Custer; Manuela Neumann; Hongbo Lu; Alexander C Wright; J Paul Taylor
Journal:  Hum Mol Genet       Date:  2010-02-10       Impact factor: 6.150

Review 7.  Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia.

Authors:  Conrad C Weihl; Alan Pestronk; Virginia E Kimonis
Journal:  Neuromuscul Disord       Date:  2009-04-19       Impact factor: 4.296

8.  Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts.

Authors:  Jouni Vesa; Hailing Su; Giles D Watts; Sabine Krause; Maggie C Walter; Barbara Martin; Charles Smith; Douglas C Wallace; Virginia E Kimonis
Journal:  Neuromuscul Disord       Date:  2009-10-13       Impact factor: 4.296

Review 9.  Management of Paget's disease of bone.

Authors:  A L Langston; S H Ralston
Journal:  Rheumatology (Oxford)       Date:  2004-06-08       Impact factor: 7.580

10.  Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia.

Authors:  Han-Xiang Deng; Wenjie Chen; Seong-Tshool Hong; Kym M Boycott; George H Gorrie; Nailah Siddique; Yi Yang; Faisal Fecto; Yong Shi; Hong Zhai; Hujun Jiang; Makito Hirano; Evadnie Rampersaud; Gerard H Jansen; Sandra Donkervoort; Eileen H Bigio; Benjamin R Brooks; Kaouther Ajroud; Robert L Sufit; Jonathan L Haines; Enrico Mugnaini; Margaret A Pericak-Vance; Teepu Siddique
Journal:  Nature       Date:  2011-08-21       Impact factor: 49.962

View more
  34 in total

1.  Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover.

Authors:  Guangbo Liu; Aaron Byrd; Amanda N Warner; Fen Pei; Eman Basha; Allison Buchanan; J Ross Buchan
Journal:  Mol Cell Biol       Date:  2020-01-30       Impact factor: 4.272

2.  In vitro studies in VCP-associated multisystem proteinopathy suggest altered mitochondrial bioenergetics.

Authors:  Angèle Nalbandian; Katrina J Llewellyn; Arianna Gomez; Naomi Walker; Hailing Su; Andrew Dunnigan; Marilyn Chwa; Jouni Vesa; M C Kenney; Virginia E Kimonis
Journal:  Mitochondrion       Date:  2015-02-25       Impact factor: 4.160

Review 3.  FTD and ALS--translating mouse studies into clinical trials.

Authors:  Lars M Ittner; Glenda M Halliday; Jillian J Kril; Jürgen Götz; John R Hodges; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2015-05-05       Impact factor: 42.937

4.  The Myoblast C2C12 Transfected with Mutant Valosin-Containing Protein Exhibits Delayed Stress Granule Resolution on Oxidative Stress.

Authors:  Carlos J Rodriguez-Ortiz; Julio C Flores; Joanna A Valenzuela; Gema J Rodriguez; Joannee Zumkehr; Diana N Tran; Virginia E Kimonis; Masashi Kitazawa
Journal:  Am J Pathol       Date:  2016-04-20       Impact factor: 4.307

5.  Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy.

Authors:  E Al-Obeidi; S Al-Tahan; A Surampalli; N Goyal; A K Wang; A Hermann; M Omizo; C Smith; T Mozaffar; V Kimonis
Journal:  Clin Genet       Date:  2018-01       Impact factor: 4.438

6.  VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle.

Authors:  Khalid Arhzaouy; Chrisovalantis Papadopoulos; Nina Schulze; Sara K Pittman; Hemmo Meyer; Conrad C Weihl
Journal:  Autophagy       Date:  2019-01-29       Impact factor: 16.016

7.  Global gene expression profiling in R155H knock-in murine model of VCP disease.

Authors:  Angèle Nalbandian; Svetlana Ghimbovschi; Zuyi Wang; Susan Knoblach; Katrina J Llewellyn; Jouni Vesa; Eric P Hoffman; Virginia E Kimonis
Journal:  Clin Transl Sci       Date:  2014-11-12       Impact factor: 4.689

8.  Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease.

Authors:  Katrina J Llewellyn; Angèle Nalbandian; Kwang-Mook Jung; Christopher Nguyen; Agnesa Avanesian; Tahseen Mozaffar; Daniele Piomelli; Virginia E Kimonis
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

9.  Targeted excision of VCP R155H mutation by Cre-LoxP technology as a promising therapeutic strategy for valosin-containing protein disease.

Authors:  Angèle Nalbandian; Katrina J Llewellyn; Christopher Nguyen; Edward S Monuki; Virginia E Kimonis
Journal:  Hum Gene Ther Methods       Date:  2015-02       Impact factor: 2.396

Review 10.  Mitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target?

Authors:  H Muyderman; T Chen
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.